AtriCure (NASDAQ:ATRC) Price Target Raised to $64.00 at Needham & Company LLC

AtriCure (NASDAQ:ATRC) had its target price hoisted by investment analysts at Needham & Company LLC from $45.00 to $64.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the medical device company’s stock. Needham & Company LLC’s price target indicates a potential upside of 30.83% from the stock’s current price.

A number of other research analysts have also issued reports on ATRC. Weiss Ratings upgraded AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 19th. Canaccord Genuity Group upped their price objective on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Raymond James Financial set a $52.00 price objective on shares of AtriCure in a report on Tuesday, July 21st. BTIG Research lifted their target price on shares of AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, August 24th. Finally, UBS Group dropped their target price on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $52.00.

AtriCure Trading Up 1.2%

Shares of AtriCure stock opened at $48.92 on Wednesday. AtriCure has a 1 year low of $25.36 and a 1 year high of $49.98. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The stock has a market cap of $2.49 billion, a PE ratio of 232.96 and a beta of 1.26. The firm has a fifty day moving average price of $38.70 and a 200 day moving average price of $32.41.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The business had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter last year, the business posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities research analysts predict that AtriCure will post 0.29 earnings per share for the current year.

Insider Activity

In related news, Director Karen Prange sold 3,564 shares of AtriCure stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total transaction of $138,283.20. Following the transaction, the director owned 22,809 shares in the company, valued at approximately $884,989.20. This trade represents a 13.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Sven Wehrwein sold 25,000 shares of the business’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $37.84, for a total value of $946,000.00. Following the transaction, the director directly owned 40,518 shares in the company, valued at $1,533,201.12. This trade represents a 38.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 53,616 shares of company stock valued at $2,149,994 in the last ninety days. 4.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On AtriCure

Hedge funds and other institutional investors have recently bought and sold shares of the company. Smartleaf Asset Management LLC boosted its holdings in AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 429 shares during the last quarter. Scotia Capital Inc. increased its holdings in shares of AtriCure by 1.2% during the 3rd quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock worth $1,328,000 after buying an additional 457 shares during the last quarter. ProShare Advisors LLC raised its position in shares of AtriCure by 6.6% during the 4th quarter. ProShare Advisors LLC now owns 8,819 shares of the medical device company’s stock valued at $349,000 after buying an additional 543 shares during the period. Captrust Financial Advisors raised its position in shares of AtriCure by 7.9% during the 4th quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company’s stock valued at $314,000 after buying an additional 579 shares during the period. Finally, Mackenzie Financial Corp lifted its holdings in AtriCure by 5.3% in the fourth quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock valued at $545,000 after acquiring an additional 683 shares during the last quarter. 99.11% of the stock is currently owned by institutional investors and hedge funds.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.